Tech Company Financing Transactions
Syntax Bio Funding Round
Syntax Bio, operating out of Chicago, secured investment capital from Astellas Venture Capital, Civilization Ventures and DCVC Bio.
Transaction Overview
Company Name
Announced On
9/18/2024
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
400 N Aberdeen, 9th Floor 9
Chicago, IL 60642
USA
Chicago, IL 60642
USA
Phone
Undisclosed
Website
Email Address
Overview
Syntax Bio is a preclinical-stage biotech company overcoming the longstanding challenges in stem cell-derived therapies by directly controlling and accelerating cell differentiation. Our Cellgorithm technology provides control over the complex developmental biology needed to manufacture stem cell-derived cell therapies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Flavin
Chief Technical Officer
Ryan Clarke
Co-Founder
Niko Balanis
Co-Founder
Brad Merrill
VP - Sales
Nick Timmins
Browse more venture capital transactions:
Prev: 9/18/2024: Frate venture capital transaction
Next: 9/18/2024: Edera venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs